Recent news coverage of ProAssurance highlights modest stock price changes since the last earnings report, with focus on earnings performance, expense management, and business momentum.

• ProAssurance's stock price increased by 0.9% since the last earnings report, with discussions on its ability to continue this trend [N3].
• The company reported Q4 earnings with improved expense management contributing to positive results [N5].
• Key metrics from the Q4 earnings report indicate earnings and revenues surpassed prior expectations [N6][N7].
• ProAssurance's Q4 profit advanced, reflecting operational improvements [N8].

ProAssurance has demonstrated operational improvements with a consolidated Non-GAAP operating ratio improving to 87.4% in 2025, driven by favorable reserve development and investment income. The Specialty P&C segment returned to underwriting profitability, and the MPL line increased renewal rates by 9% while deploying advanced analytics. The company’s performance-based executive compensation aligns management incentives with financial results. The pending merger with The Doctors Company may provide strategic benefits and scale [S1][N3][N5][N6][N7][N8].

Risks include the competitive and inflationary pressures in the medical professional liability and workers' compensation insurance markets, which could impact underwriting results. The Workers' Compensation segment did not achieve threshold performance on its segment-specific operating ratio metric, indicating challenges in that line. The pending merger introduces integration risks and potential disruptions. Executive compensation arrangements related to the merger may also present governance considerations [S1].

ProAssurance's moat is supported by its specialized focus on medical professional liability insurance and workers' compensation, lines that require deep underwriting expertise and risk management capabilities. The company has implemented data analytics and automated underwriting platforms to enhance risk assessment and operational efficiency. Its ability to maintain underwriting discipline and achieve rate adequacy in competitive markets contributes to its competitive positioning. The company's strong corporate culture and experienced management team further support its operational effectiveness [S1].

• Market and Underwriting Risks: The insurance lines ProAssurance operates in are subject to competitive pricing pressures, claims severity, and medical cost inflation, which can adversely affect underwriting results and profitability.
• Merger and Integration Risks: The ongoing merger with The Doctors Company presents risks related to integration, cultural alignment, and potential operational disruptions.
• Executive Compensation and Governance Risks: Compensation arrangements, including payments related to the merger, may pose governance challenges and affect management incentives.

• ProAssurance Corporation is incorporated in Delaware and trades on the New York Stock Exchange under the ticker PRA [S1].
• As of December 31, 2025, ProAssurance reported annual revenue of approximately $1.098 billion USD and net income of about $50.9 million USD [S1].
• The company reported basic and diluted earnings per share of $0.99 for the fiscal year ended December 31, 2025 [S1].
• Cash and cash equivalents totaled approximately $36.5 million USD as of December 31, 2025 [S1].
• ProAssurance's board of directors includes experienced professionals with backgrounds in law, finance, healthcare, and insurance sectors, with detailed biographies disclosed in the 10-K/A [S1].
• The company operates in the insurance sector, with specific focus on medical professional liability and workers' compensation insurance lines [S1].
• In 2025, ProAssurance achieved a consolidated Non-GAAP operating ratio of 87.4%, improving from 93.7% in 2024, driven by favorable prior year reserve development and improved investment income [S1].
• The Specialty P&C segment achieved its first underwriting profit since 2017, emphasizing rate adequacy and underwriting discipline [S1].
• The Medical Professional Liability (MPL) line implemented data analytics and automated underwriting to reduce risk and improve efficiency, with renewal rate increases of 9% in a competitive market [S1].
• The Workers' Compensation segment adopted new tools including AI agents and a physical therapy network to manage costs, with improved operating ratios due to investment income [S1].
• The company maintains a strong corporate culture as measured by internal surveys despite the pending merger transaction with The Doctors Company [S1].
• ProAssurance's executive compensation includes a mix of salary, restricted stock units, performance shares, and annual incentives tied to operating ratios and individual performance metrics [S1].
• In 2025, the CEO's annual incentive award was 177% of base salary, reflecting strong financial and operational performance [S1].
• The company is undergoing a merger with The Doctors Company, with related executive compensation arrangements disclosed [S1].
• Recent news coverage highlights ProAssurance's modest stock price movement since the last earnings report and discusses its earnings performance and expense management [N3][N5][N6][N7][N8].